DOVER, Del., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Metatron (OTC:MRNJ), a technology pioneer specializing in the accelerated release of over 2000 apps including Cannabis based, CBD, and Vaporized™ secure chat apps via iTunes and Google Play, is pleased to report the final stage development of Bitweed™, a cryptocurrency transaction and tracking app for Marijuana dispensaries and consumers.
A biotech company now distributes the Metatron developed and recent updated Cannaboids™ app under its own iTunes account with Google Play soon to follow.
“Bitcoin has risen 1500% this year, about 85% in the last few weeks and Futures contracts open as of yesterday . With Cannabis legal in about 29 states, and Canada making recreational Marijuana legal, both industries are now mainstream. Payment solutions are needed for dispensaries and customers so we plan on integrating the upcoming Bitweed™ and the popular Cannaboids™ apps to make this process more efficient for retailers and consumers We expect Bitweed™ to eventually evolve into its own cryptocoin”” said CEO Joe Riehl
New Alliance Biosciences, Inc., formerly Sanguine Corporation (through its subsidiary, SGN LifeSciences, is engaged in discovering, developing and commercializing novel biotechnologies.
The company is focused on the development and commercialization of perfluorocarbon based therapeutic oxygen carriers. The Company’s core product, PHER-02, is a perfluorocarbon emulsion.
Our two companies plan to conduct a shared roll-out of mobile applications geared to solve issues in the cannabis payment space using Blockchain technology and Bitcoin options. These apps will be marketed under Cannaboids™ (www.cannaboids.com), and Bitweed™ brands while New Alliance provides necessary biotech and medical research for Metatron (www.Metatroninc.com) bio-tech app development.
This announcement coincides with the launch of http://www.icocryptoblockchain.com, the premier one-stop website soon to be app with the latest cryptocurrency news, education, editorials, market capitalizations, trade volume and ICO alerts.
“This is a unique animal unlike any commodity we've looked at before," said Andrew Busch, the CFTC's chief market intelligence officer.
According to industry estimates, Bitcoin and the over 1000 other cryptocoins are now worth over $300 billion, only a year ago they were worth about 1 Billion. Today $10 billion+ in digital tokens change hands daily and even big players such as Goldman Sachs, Visa, Capital One, Nasdaq, and the New York Stock Exchange have invested in blockchain technology. We expect Bitcoin market cap to surpass the S&P index and eventually even Gold trading in overall value.
According to Forbes By 2020, the Cannabis industry is expected to create more jobs than manufacturing. Overall legal marijuana sales are set to increase from about 7 billion dollars in 2016 to 26.5 billion dollars 2020. Since Canada recently legalized recreational marijuana nationwide, it will result in an additional 23 Billion dollar added to the industry over the same time period according to Delotte.
Metatron an industry leader in the field of mobile app development with over 2000 apps created, millions in sales and downloads historically, has partnered with high profile companies and clients worldwide and is poised to revolutionize the exploding crypto and cannabis industries.
Through its app development division i-Mobilize™, and as a pioneer in emerging markets, Metatron was the first company to release any Cannabis related apps on iTunes and has extensive experience in processing payments through its Just Data Billing division. Release date for the BitWeed™ app is expected first quarter of next year.
Metatron is also pleased to announce a formal offer to Buzzlink.com, a cannabis e-commerce platform for dispensaries and other retailers. Buzzlink.com will be financed partially by the issuance of preferred B series shares and we now accept Bitcoin, soon other Coins.
Metatron approved investors can acquire Series B shares in blocks of various sizes. The first round investors will receive the highest discount. Series B shares can be redeemed through the Company, are immune to reverse splits, and will convert at 1 B share to 50,000 common shares at a discount. There are a limited number of B shares available and Metatron reserves the right to end offering at any time.
Details available at:
Google Play: https://play.google.com/store/apps/developer? id=Metatron+Inc
Correction from last PR:
In our last press release we referred to Sanguine BioSciences website (www.sanguinebio.com) and company in error and our app contract is with Sanguine Inc. Sanguine Inc. had a recent name change and is the same space. We are not affiliated or have any business with the Sanguine Biosciences, and updated our various news channels as soon as it was brought to our attention.
Any statements made in this press release which are not historical facts contain certain forward-looking statements, as such term is defined in the Private Litigation Reform Act of 1995, concerning potential developments affecting the business, prospects, financial condition and other aspects of the company to which this release pertains. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results of the specific items described in this release, and the company’s operations generally, to differ materially from what is projected in such forward-looking statements. Although such statements are based upon the best judgments of management of the company as of the date of this release, significant deviations in magnitude, timing and other factors may result from business risks and uncertainties including, without limitation, the company’s need for additional financing, which is not assured and which may result in dilution of shareholders, the company’s status as a small company with a limited operating history, dependence on third parties and the continuing popularity of the iOS/Android operating systems, general market and economic conditions, technical factors, receipt of revenues, and other factors, many of which are beyond the control of the company. Although we believe that the expectations and statements reflected in the forward-looking statements are reasonable and accurate at time of release, we cannot guarantee future results, levels of activity, performance, or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of such statements, and we disclaim any obligation or liability to update information contained in any forward-looking statement or errors in press releases. Metatron does not grow, sell or distribute any substances that violate United States Law or the Controlled Substances Act.
Metatron, Inc. 302-861-0431 email@example.com SOURCE: Metatron, Inc